Company intelligence / Profile preview
RosVivo Therapeutics
Reno, Nevada, United Statesrosvivo.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pre-clinical stage biotech developing miRNA-based therapies for metabolic diseases including diabetes; RSVI-301 shows efficacy in restoring beta cell function and reducing insulin resistance in animal models with fewer side effects than GLP-1 agonists.
- Therapeutic areas
- GastroenterologyEndocrinologyInfectious Diseases
- Modalities
- miRNA
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Eli Lilly and Company
Beyond the preview
Go deeper on RosVivo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RosVivo Therapeutics.